RSPH14 regulates the proliferation, cell cycle progression, and apoptosis of non-small cell lung cancer cells

Ke Ma¹,², Jun Peng², Hao Rong², Yanhua Jiang², Huachuan Zhang², Jiang Zhu², Bo Xiao², Peng Tang¹, Jintao He² and Zhentao Yu¹

¹ Department of Esophageal Cancer, Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin’s Clinical Research Center for Cancer, National Clinical Research Center of Cancer, Tianjin, China
² Department of Thoracic Surgery, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China

Keywords
apoptosis; RSPH14; Non-small cell lung cancer; proliferation; cell cycle; biomarker

Correspondence
Z. Yu, Department of Esophageal Cancer, Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy of Tianjin City, Huanhuxi Road, Tiyuanbei, HeXi District, Tianjin, 300060, China
E-mail: yztao2015@163.com
J. He, Department of Thoracic Surgery, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
E-mail: hjtabc3@163.com

(Received 27 September 2020, revised 5 March 2021, accepted 3 August 2021)
doi:10.1002/2211-5463.13266

Non-small cell lung cancer (NSCLC) is the most common subtype of lung cancer, and it is characterized by a high incidence. It is important to understand the molecular mechanisms that determine the progression and metastasis of NSCLC in order to develop more effective therapies and identify novel diagnostic indicators of NSCLC. RSPH14 has been reported to be related to multiple human diseases, including duodenal adenocarcinoma and meningiomas, but the role of RSPH14 in NSCLC remains unclear. The present study aimed to investigate the molecular function and clinical significance of RSPH14 in NSCLC. Analyses of public datasets and clinical samples demonstrated that RSPH14 expression was upregulated in NSCLC samples compared with normal samples. In addition, high RSPH14 expression was associated with a shorter overall survival time in patients with NSCLC. Notably, RSPH14 knockdown suppressed the proliferation and cell cycle progression and enhanced the apoptosis of NSCLC cells. Mechanically, tandem mass tag analysis demonstrated that RSPH14 can affect multiple processes, including the AMPK signaling pathway, calcium ion import regulation, glucose transmembrane transporter activity, and glucose transmembrane transport. Taken together, the results of the present study suggest that RSPH14 may be a promising prognostic factor and therapeutic target for NSCLC.

Histologically, lung cancer is classified into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) [1]. NSCLC is the most common subtype of lung cancer, accounting for 80% of all cases (1,2). However, NSCLC is more resistant to chemotherapy compared with SCLC [2]. Over the past decades, the incidence and mortality rates of NSCLC have increased rapidly. In addition, the 5-year survival rate of NSCLC remains low compared with other common cancers, such as colorectal, breast, and prostate cancers [2]. The 5-year survival rates for patients with advanced and metastatic NSCLC are 24 and 4%, respectively [3]. Previous studies have reported a series of regulators involved in controlling NSCLC metastasis, including TWIST1 [4], PTCH1 [5], and TGF-β-induced long noncoding RNAs (IncRNAs) [6]. Identification of further biomarkers is urgently required to improve the prognosis and survival of patients with NSCLC.

Cancer is caused by the abnormal regulation of cell cycle progression and apoptosis [7]. Apoptosis is

Abbreviations
NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer; IncRNAs, long noncoding RNAs; shRNA, short hairpin RNA; CCK-8, cell counting Kit-8; PI, propidium iodide; KEGG, kyoto encyclopedia of genes and genomes.
affected by intracellular and/or extracellular signals and is characterized by cell morphological changes that target death, including nuclear division and concentration, mitochondrial outer membrane permeability, membrane hemorrhage, cell atrophy, and apoptotic body formation [8]. Recently, activation of apoptosis has been proven to be a therapeutic biomarker for cancer by decreasing the accumulation of cancer cells [8]. In NSCLC, several novel apoptosis regulators have been identified, including MINCR [9,10] and LINC00961 [11]. MINCR is a cell cycle and apoptosis regulator in NSCLC [9,10], while IncRNA LINC00961 suppresses tumor growth and promotes cell apoptosis in NSCLC [11]. However, the molecular mechanisms underlying the regulation of NSCLC remain unclear.

RSPH14 is a new gene with a slight homology to a yeast VAC8 protein, which transports aminopeptidase I from the cytoplasm to the vacuole in vacuole inheritance [12]. RSPH14 has been reported to be heterozygously or homozygously lost in pediatric rhabdoid tumors [13]. Recently, several studies also demonstrated this gene was related to multiple human diseases, such as duodenal adenocarcinoma [14], congenital heart disease [15], meningiomas [16], and circulating parathyroid hormone formation [17]. However, the role of RSPH14 in NSCLC remains unclear. The present study aimed to investigate the function and prognostic value of RSPH14 in NSCLC. The function of RSPH14 in inducing the proliferation and apoptosis of NSCLC cells and the role of the AMPK signaling pathway in this process were investigated, in order to determine whether RSPH14 may serve as a promising biomarker for the treatment of patients with NSCLC.

Materials and methods

Patients and tissue samples

A total of nine NSCLC tissue samples were collected from patients with NSCLC at Si Chuan Cancer Hospital between 2016 and 2018, according to postoperative pathological reports. The present study was approved by the Ethics Committee of the Si Chuan Cancer Hospital, and written informed consent was provided by all patients prior to the study initiation. The use of human samples complies with the standards stipulated in the Declaration of Helsinki.

Bioinformatics analysis

The Kaplan–Meier Plotter database (http://www.kmplot.com) was used to determine the prognostic value of RSPH14 in NSCLC. The Database for Annotation, Visualization and Integrated Discovery (version 6.7; http://david.abcc.ncifcrf.gov) was used to perform functional analysis [18].

Lentiviral constructs and transfection

A recombinant lentiviral vector carrying RSPH14 short hairpin (sh)RNA was constructed using standard molecular techniques. The expression of RSPH14 shRNA in infected cells was verified via reverse transcription-quantitative (RT-q)PCR analysis. The RSPH14 shRNA sequence was as follows: CCGGGATCATCACGAAAGGCTGATCTCGAGATCATCGTTCAGTATCAGACCTTTGCTGATGATCTTTTTG. An empty vector was used as control shRNA. The control shRNA sequence was as follows: CCGGTTCTCCGAACGTGTACGTCTCGAGACGTGACACGTTCGGAATTTTTG.

Cell culture

NCI-H1975, A549, and H1299 cells were purchased from the American Type Culture Collection and maintained in RPMI-1640 medium supplemented with 10% fetal bovine serum (HyClone; Cytiva), at 37° C in 5% CO2.

RT-qPCR

Total RNA was extracted from cells using TRIzol® reagent (Invitrogen; Thermo Fisher Scientific, Waltham, MA, USA) and reverse-transcribed into cDNA using the PrimeScript™ RT Reagent kit (Takara Biotechnology, Shiga, Japan). qPCR was subsequently performed using the SYBR® Green qPCR kit (Takara Biotechnology), on the ABI StepOnePlus real-time PCR system (Applied Biosystems; Thermo Fisher Scientific). The following thermocycling conditions were used for qPCR: initial denaturation at 95 °C for 30 s; followed by 40 cycles at 95 °C for 5 s and 60 °C for 34 s, according to the manufacturer’s protocol. The following primer sequences were used for PCR: RSPH14 forward, 5'-AGAAGAACGAATGGTTGAGAT-3' and reverse, 5'-TCTCTGGATATTTGCAGTCAGT-3'; and GAPDH forward, 5'-TCTCTGGATATTTGCAGTACGT-3' and reverse, 5'-TCTCTGGATATTTGCAGTACGT-3'; and GAPDH forward, 5'-TCTCTGGATATTTGCAGTACGT-3' and reverse, 5'-TCTCTGGATATTTGCAGTACGT-3'. Relative expression levels were calculated using the 2−ΔΔCq method and normalized to the internal reference gene GAPDH.

Plate analysis with the adherent cell cytometry system Celigo®

Briefly, cells were stained with fluorescent nuclear stain (Hoechst nuclear stain, 2.6 μg/mL−1; Invitrogen; Thermo Fisher Scientific). As previously described [18], the
adherent cell cytometry system was used to quantify the fluorescence expression of cells. Use equipped with bright field and fluorescence channels adherent cells cytometry analysis plate: Hoechst blue (nuclear staining of DAPI) filter and siGLO green filter. The gating parameters of each fluorescence channel were adjusted to exclude background noise and other nonspecific signals. Quantitative analysis for each fluorescence channel and individual well was performed using the Celigo® system, including the total count of gated events and the average integrated red fluorescence intensity.

**Cell proliferation assay**

The Cell Counting Kit-8 (CCK-8) assay was performed to assess cell viability following infection with shRSPH14. A549 and H1299 cells were seeded into 96-well plates at a density of 5000 cells-well$^{-1}$. Cell viability was assessed at days 0–4, according to the manufacturer’s protocol. Following incubation with CCK-8 reagent for 4 h, cell viability was analyzed at a wavelength of 490 nm using a PowerWave XS microplate reader (BioTek Instruments, Winooski, VT, USA). All experiments were performed in triplicate.

**Adherent cell cytometry system Celigo® assay**

Cells infected with shRSPH14 or control shRNA were trypsinized and seeded into 96-well plates at a density of 2000 cells-well$^{-1}$. Fluorescence was measured every day for a total of 5 days using the Celigo® system, as previously described.

**Cell cycle assay**

Cells infected with shRSPH14 or control shRNA were harvested and washed three times with PBS. Cells were subsequently incubated with PBS containing 0.03% Triton X-100, 100 ng·mL$^{-1}$ RNase A, and 50 ng·mL$^{-1}$ propidium iodide (PI) for 15 min. Cell cycle distribution was analyzed using a FACSanto flow cytometer (BD Biosciences, San Jose, CA, USA) and MODFIT LT 3.0 software. All experiments were performed in triplicate.

**Cell apoptosis assay**

Cells infected with shRSPH14 or control shRNA were harvested and washed three times with PBS. Cells were subsequently treated with 1X binding buffer and stained with 10 μL Annexin V-APC staining solution (eBioscience; Thermo Fisher Scientific). Apoptotic cells were subsequently analyzed using a FACSanto flow cytometer (BD Biosciences) and MODFIT LT 3.0 software. All experiments were performed in triplicate.

**Western blotting**

Total protein was extracted from cells using RIPA buffer (Thermo Fisher Scientific). Total protein was quantified using the Pierce BCA protein detection kit (Thermo Fisher Scientific) and 20 μg of protein/lane was separated by 10% SDS/PAGE. The separated proteins were subsequently transferred onto PVDF membranes (EMD Millipore) and blocked with TBST with 5% milk at room temperature for 2–4 h. The membranes were incubated with primary antibodies against RSPH14 (1:1000; cat. no. A15430; ABclonal Biotech Co., Boston, MA, USA) and GAPDH (1:1000; cat. no. sc-32233; Santa Cruz Biotechnology, Santa Cruz, CA, USA) overnight at 4 °C. Following the primary incubation, membranes were incubated with horseradish peroxidase-conjugated goat antimouse IgG secondary antibodies (1:5000; cat. no. abs20001ss; ABSIN) for 2 h at 37 °C. Protein bands were visualized using enhanced chemiluminescence (Bio-Rad Laboratories, Inc.) and analyzed using GRAPHPAD PRISM 6.0 software (GraphPad Software Inc., La Jolla, CA, USA).

**Statistical analysis**

Statistical analysis was performed using GRAPHPAD 6.0 software (GraphPad Software Inc.). Data are presented as the mean ± standard deviation. Student’s *t*-test or Mann–Whitney *U*-test were used to compare differences between groups. Survival analysis was performed using the Kaplan–Meier method and log-rank test. The association between RSPH14 expression and cancer prognosis was assessed. *P* < 0.05 was considered to indicate a statistically significant difference.

**Results**

**Expression of RSPH14 in NSCLC**

To determine whether RSPH14 is involved in the regulation of NSCLC progression, RSPH14 mRNA expression was detected in NSCLC tissues and corresponding normal tissues. The results demonstrated that RSPH14 mRNA expression was upregulated in NSCLC tissues compared with normal tissues (Fig. 1A and B). The specific expression characterizations of RSPH14 indicated that this gene may be associated with the progression of NSCLC.

**RSPH14 is associated with poor prognosis in NSCLC**

The characteristics of patients with high and low RSPH14 mRNA expression levels were compared. Patients were divided into two groups (high and low
RSPH14 expression was detected in NSCLC cells. The results demonstrated that RSPH14 mRNA was highly expressed in H1975, A549, and H1299 cells relative to GAPDH RNA levels (Fig. 2A). The effect of RSPH14 on NSCLC cells was subsequently investigated. A549 and H1299 cells were infected with shRSPH14 to suppress RSPH14 protein expression (Fig. 2B-F). The results demonstrated that cell proliferation significantly decreased in shRSPH14-transfected A549 and H1299 cells compared with control cells (Fig. 3A and B). In addition, RSPH14 knockdown suppressed cell viability by 50 and 60% in A549 and H1299 cells, respectively, at day 3 compared with the control groups.

Celigo® analysis was performed to assess the effect of RSPH14 knockdown on NSCLC cell proliferation. As presented in Fig. 3, the number of A549 (Fig. 3C and D) and H1299 (Fig. 3C and E) cells decreased by 88.3 and 65.0%, respectively, following RSPH14 knockdown compared with the control group.

**RSPH14 expression is upregulated in NSCLC cells and is associated with cell proliferation**

RSPH14 mRNA expression was detected in NSCLC cells. The results demonstrated that RSPH14 mRNA was highly expressed in H1975, A549, and H1299 cells relative to GAPDH RNA levels (Fig. 2A). The effect of RSPH14 on NSCLC cells was subsequently investigated. A549 and H1299 cells were infected with shRSPH14 to suppress RSPH14 protein expression (Fig. 2B-F). The results demonstrated that cell proliferation significantly decreased in shRSPH14-transfected A549 and H1299 cells compared with control cells (Fig. 3A and B). In addition, RSPH14 knockdown suppressed cell viability by 50 and 60% in A549 and H1299 cells, respectively, at day 3 compared with the control groups.

Celigo® analysis was performed to assess the effect of RSPH14 knockdown on NSCLC cell proliferation. As presented in Fig. 3, the number of A549 (Fig. 3C and D) and H1299 (Fig. 3C and E) cells decreased by 88.3 and 65.0%, respectively, following RSPH14 knockdown compared with the control group.

**RSPH14 expression is upregulated in NSCLC cells and is associated with cell proliferation**

RSPH14 mRNA expression was detected in NSCLC cells. The results demonstrated that RSPH14 mRNA was highly expressed in H1975, A549, and H1299 cells relative to GAPDH RNA levels (Fig. 2A). The effect of RSPH14 on NSCLC cells was subsequently investigated. A549 and H1299 cells were infected with shRSPH14 to suppress RSPH14 protein expression (Fig. 2B-F). The results demonstrated that cell proliferation significantly decreased in shRSPH14-transfected A549 and H1299 cells compared with control cells (Fig. 3A and B). In addition, RSPH14 knockdown suppressed cell viability by 50 and 60% in A549 and H1299 cells, respectively, at day 3 compared with the control groups.

Celigo® analysis was performed to assess the effect of RSPH14 knockdown on NSCLC cell proliferation. As presented in Fig. 3, the number of A549 (Fig. 3C and D) and H1299 (Fig. 3C and E) cells decreased by 88.3 and 65.0%, respectively, following RSPH14 knockdown compared with the control group.

**RSPH14 expression is upregulated in NSCLC cells and is associated with cell proliferation**

RSPH14 mRNA expression was detected in NSCLC cells. The results demonstrated that RSPH14 mRNA was highly expressed in H1975, A549, and H1299 cells relative to GAPDH RNA levels (Fig. 2A). The effect of RSPH14 on NSCLC cells was subsequently investigated. A549 and H1299 cells were infected with shRSPH14 to suppress RSPH14 protein expression (Fig. 2B-F). The results demonstrated that cell proliferation significantly decreased in shRSPH14-transfected A549 and H1299 cells compared with control cells (Fig. 3A and B). In addition, RSPH14 knockdown suppressed cell viability by 50 and 60% in A549 and H1299 cells, respectively, at day 3 compared with the control groups.

Celigo® analysis was performed to assess the effect of RSPH14 knockdown on NSCLC cell proliferation. As presented in Fig. 3, the number of A549 (Fig. 3C and D) and H1299 (Fig. 3C and E) cells decreased by 88.3 and 65.0%, respectively, following RSPH14 knockdown compared with the control group.
Fig. 2. The suppressing effects of downregulated RSPH14 in NSCLC cell with shRSPH14 transfection. (A) The expression levels of RSPH14 were detected in 3 CRC cell lines including H1975, A549, and H1299 cells by using RT-qPCR assay. (B) The downregulation of RSPH14 in protein levels with lentivirus-mediated shRSPH14 in A549 cells by using western blot assay with primary antibodies against RSPH14 (1:1000; cat. no. A15430; ABclonal Biotech Co.) and GAPDH (1:1000; cat. no. sc-32233; Santa Cruz Biotechnology). (C) The infection efficiency in A549 cells was detected by fluorescence imaging. Magnification ×100. (D) The downregulation of RSPH14 in mRNA levels with lentivirus-mediated shRSPH14 in A549 cells by using RT-qPCR assay. (E) The infection efficiency in H1299 cells was detected by fluorescence imaging. Magnification ×100. (F) The downregulation of RSPH14 in mRNA levels with lentivirus-mediated shRSPH14 in H1299 cells by using RT-qPCR assay. Scale bars: 400 μm. Student’s t-test was used to compare differences between groups. ***P < 0.001 vs. control. All data are shown as mean ± SD of three independent experiments.

K. Ma et al. RSPH14 promotes NSCLC progression
RSPH14 promotes NSCLC progression

K. Ma et al.

(A) OD450 vs Time (day)

(B) OD450 vs Time (day)

(C)

Day 1 Day 2 Day 3 Day 4 Day 5

A549

shCtrl shRSPH14

H1299

shCtrl shRSPH14

(D) Cell count vs Time

(E) Cell count vs Time
RSPH14 knockdown inhibits cell cycle progression and induces apoptosis of NSCLC cells

Increasing evidence suggests that cancer is caused by an imbalance between cell cycle progression and apoptosis. Thus, the present study investigated whether RSPH14 modulates the cell cycle and apoptosis of NSCLC cells.

Flow cytometry was performed to assess changes in the cell cycle. RSPH14 knockdown significantly increased the percentages of A549 (Fig. 4A and B) and H1299 (Fig. 4C and D) cells in the G1 phase, while the number of cells in the S phase notably decreased. Taken together, these results suggest that RSPH14 enhances cell cycle progression in NSCLC.

The present study investigated whether RSPH14 is involved in promoting cell proliferation by inducing cell apoptosis. Flow cytometry combined with Annexin V-APC single-color staining was performed to assess the effect of RSPH14 on cell apoptosis. The results demonstrated that the number of apoptotic A549 (Fig. 5A and B) and H1299 (Fig. 5C and D) cells markedly increased following RSPH14 knockdown, which was confirmed by the significant increase of Annexin V-APC-positive cells. Collectively, these results suggest that RSPH14 knockdown notably enhances NSCLC cell apoptosis.

Proteomics analysis and bioinformatics analysis of RSPH14 in NSCLC

Given that the underlying molecular mechanisms of RSPH14 in NSCLC remain unknown, proteomics analysis was performed to assess the changes in RSPH14 protein expression following RSPH14 knockdown in A549 cells. The protein expression levels of 175 genes were downregulated, while the protein levels of 48 genes were upregulated following RSPH14 knockdown in A549 cells (Fig. 6A).

Gene set enrichment analysis demonstrated that RSPH14 targets were involved in calcium ion import regulation, glucose transmembrane transporter activity, glucose transmembrane transport, integrin-mediated signaling pathway, alpha-2B and alpha-2C adrenergic receptor binding, cellular response to norepinephrine stimulus, and adenylate cyclase-activating G protein-coupled receptor signaling pathway, and cellular response to increased oxygen levels (Fig. 6B). KEGG pathway analysis indicated that RSPH14 targets were associated with the regulation AMPK signaling pathway, rheumatoid arthritis, collecting duct acid secretion, streptomycin biosynthesis, synaptic vesicle cycle, epithelial cell signaling in *Helicobacter pylori* infection, and mucin type O-glycan biosynthesis (Fig. 6C).

Discussion

NSCLC is the most common subtype of lung cancer. It is important to understand the molecular mechanisms involved in the development of NSCLC to develop effective therapies and identify novel biomarkers for NSCLC. Over the past decades, several key regulators were revealed to modulate cancer cell proliferation, cell cycle, and apoptosis in NSCLC, such as NUP37 [19], ARHGAP24 [20], and PTEN [21]. Recent studies have demonstrated that RSPH14 is associated with human diseases, such as in rhabdoid tumors, duodenal adenocarcinoma [14], congenital heart disease [15], meningiomas [16], and circulating parathyroid hormone formation [17]. However, the molecular mechanism underlying the regulatory role of RSPH14 in NSCLC tumorigenesis remains unknown.

In this study, our results demonstrated that RSPH14 expression was upregulated in NSCLC samples compared with that in normal samples. In addition, bioinformatics analysis demonstrated that high RSPH14 expression was associated with a shorter overall survival time in patients with NSCLC. Taken together, these results suggest that RSPH14 may be a potential biomarker in NSCLC. The biological functions of RSPH14 in human cancers remain largely unknown. The results of the present study suggest that RSPH14 may act as an important regulator of the progression of NSCLC. Notably, downregulated RSPH14 expression was associated with decreased cell proliferation. In addition, the results demonstrated that RSPH14 was involved in regulating cancer apoptosis and cell cycle. RSPH14 knockdown markedly promoted cell cycle arrest in the G1 phase and cell apoptosis compared with the control group. Collectively, these
results suggest that RSPH14 acts as an oncogene in NSCLC.

Notably, as an energy sensor, AMPK has been reported to be a crucial regulator of cell apoptosis, proliferation, and autophagy [22]. AMPK modulates cell cycle arrest via multiple mechanisms. For example, AMPK can regulate p53 proteasomal turnover by phosphorylating MDMX. In addition, AMPK directly phosphorylates p53 to increase its stability and initiate cell cycle arrest [23]. AMPK is a key apoptosis regulator, which functions by modulating the regulation and stability of the p53,
mTORC1, and JNK pathways [24,25]. In NSCLC, AMPK was also reported to have a key role. For example, AMPK-dependent phosphorylation of HDAC8 promotes lung cancer cell survival under glucose starvation via regulating PGM1 expression [26]. AMPK mediated the effect of Polyphyllin I on the growth and autophagy of NSCLC. A recent study showed AMPK-mediated induction of lysosomal function supports NSCLC cell fitness [27]. AMPK is required to support tumor growth in murine Kras-dependent lung cancer models [28]. However, the upstream regulators of AMPK remained largely unclear. Interestingly, the results of the present study demonstrated that RSPH14 was associated with the regulation of AMPK signaling pathway via multiple genes. Of note, proteomics and bioinformatic analyses were performed in this study to explore the underlying molecular mechanisms of RSPH14 in NSCLC. Besides AMPK signaling, multiple cancer-related pathways were also revealed to be related to RSPH14, such as calcium ion import regulation, glucose transmembrane transporter activity, glucose transmembrane transport, collecting duct acid secretion, streptomycin biosynthesis, and synaptic vesicle cycle.

Despite this study for the confirmed that RSPH14 is a key cell cycle and apoptosis regulator in NSCLC, several limitations should be noted. Firstly, more clinical samples will be collected and used for the validation of the correlation between clinical parameters and RSPH14 expression. Secondly, the effects of RSPH14 on AMPK signaling should be confirmed using

Fig. 5. RSPH14 knockdown enhanced cell apoptosis in NSCLC. (A, C) The apoptosis of A549 (A) and H1299 (C) cells transfected with shRSPH14 and negative control shRNA was determined using the FACSanto flow cytometer assay. (B, D) A549 (B) and H1299 (D) cell apoptosis was analyzed using a FACSanto flow cytometer (BD Biosciences) and MODFIT LT 3.0 software. Student’s t-test was used to compare differences between groups. ***P < 0.001 vs. control. All data are shown as mean ± SD of three independent experiments.
experimental assays. Thirdly, the in vivo assays should be performed to further demonstrate the effect of RSPH14 on NSCLC proliferation and apoptosis.

In conclusion, the results of the present study demonstrated that RSPH14 promoted NSCLC cell proliferation by suppressing cell cycle arrest and apoptosis. In addition, clinical analysis demonstrated that RSPH14 expression was upregulated in NSCLC samples, which was associated with a shorter overall survival time of patients with NSCLC. Proteomics analysis demonstrated that RSPH14 modulated AMPK signaling. Taken together, these results suggest
that RSPH14 may be a promising biomarker for the prognosis and treatment of patients with NSCLC.

Acknowledgments
This study was supported by the National Natural Science Foundation of China (Grant Number: 81772619, 82002551), Clinical Trial Project of Tianjin Medical University (Grant Number: 2017kyic006), Bethune Charitable Foundation (Grant Number: HZB-20190528-18), and Science and Technology Project of Tianjin Municipal Health Commission (KJ20119).

Data accessibility
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions
All authors agree to be accountable for all aspects of the work is appropriately investigated and resolved. All authors read and approved the final manuscript.

References
1. Herbst RS, Morgensztern D and Boshoff C (2018) The biology and management of non-small cell lung cancer. Nature 553, 446–454.
2. Molina JR, Yang P, Cassivi SD, Schild SE and Adjei AA (2008) Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 83, 584–594.
3. Cheng Y, Chen Y, Zang G, Chen B, Yao J, Zhang W, Wang H, Yu L, He P, Zhang Y et al. (2020) Increased expression of TAP is predictive of poor prognosis in patients with non-small cell lung cancer. Cancer Manag Res 12, 1941–1946.
4. Duan F, Hao D, Xu W, Zhong X and Luo T (2019) Correlations of twist expression with pathological and computed tomography (CT) characteristics and prognosis of non-small cell lung cancer (NSCLC). Med Sci Monit 25, 977–983.
5. Wan X, Kong Z, Chu K, Yi C, Hu J, Qin R, Zhao C, Fu F, Wu H, Li Y et al. (2018) Co-expression analysis revealed PTCH1-3’UTR promoted cell migration and invasion by activating miR-101-3p/SLC39A6 axis in non-small cell lung cancer: implicating the novel function of PTCH1. Oncotarget 9, 4798–4813.
6. Zheng S, Lu Z, Liu C, Wang X, Jin R, Mao S, Huang J, Lei Y, Zhang C, Sun N et al. (2019) The TGFBeta-Induced Long Non-coding RNA TBULC Promotes the Invasion and Migration of Non-small Cell Lung Cancer Cells and Indicates Poor Prognosis. Front Oncol 9, 1340.
7. Evan GI and Vousden KH (2001) Proliferation, cell cycle and apoptosis in cancer. Nature 411, 342–348.
8. Redz-Dutordoirm M and Averill-Bates DA (2016) Activation of apoptosis signalling pathways by reactive oxygen species. Biochim Biophys Acta 1863, 2977–2992.
9. Chen S, Gu T, Lu Z, Qiu L, Xiao G, Zhu X, Li F, Yu H, Li G and Liu H (2019) Roles of MYC-targeting long non-coding RNA MINCR in cell cycle regulation and apoptosis in non-small cell lung Cancer. Respir Res 20, 202.
10. Wang J, Ding M, Zhu H, Cao Y and Zhao W (2019) Up-regulation of long noncoding RNA MINCR promotes non-small cell lung cancer growth by negatively regulating miR-126/SLC7A5 axis. Biochem Biophys Res Commun 508, 780–784.
11. Huang Z, Lei W, Tan J and Hu HB (2018) Long noncoding RNA LINC00961 inhibits cell proliferation and induces cell apoptosis in human non-small cell lung cancer. J Cell Biochem 119, 9072–9080.
12. Zhou J, Fogelgren B, Wang Z, Roe BA and Biegel JA (2000) Isolation of genes from the rhabdoid tumor deletion region in chromosome band 22q11.2. Gene 241, 133–141.
13. Matana A, Brdar D, Torlak V, Boutin T, Popovic M, Gunjaca I, Kolic I, Boraska Perica V, Punda A, Polasek O et al. (2018) Genome-wide meta-analysis identifies novel loci associated with parathyroid hormone level. Med Med 24, 15.
14. Yuan W, Zhang Z, Dai B, Wei Q, Liu J, Liu Y, Liu Y, He L and Zhou D (2016) Whole-exome sequencing of duodenal adenocarcinoma identifies recurrent Wnt/beta-catenin signaling pathway mutations. Cancer 122, 1689–1696.
15. Hou HT, ChenHX, Wang XL, Yuan C, Yang Q, Liu ZG and He GW (2020) Genetic characterisation of 22q11.2 variations and prevalence in patients with congenital heart disease. Arch Dis Child 105, 367–374.
16. Wozniak K, Piaskowski S, Gresner SM, Golanska E, Bieniek E, Bigoszewska K, Sikorska B, Szybka M, Kuleczycka-Wojdala D, Zakrzewska M et al. (2008) BCR expression is decreased in meningiomas showing loss of heterozygosity of 22q within a new minimal deletion region. Cancer Genet Cytofogenet 183, 14–20.
17. Robinson-Cohen C, Lutsey PL, Kleber ME, Nielson CM, Mitchell BD, Bis JC, Eny KM, Portas L, Eriksson...
J, Lorentzon M et al. (2017) Genetic variants associated with circulating parathyroid hormone. *J Am Soc Nephrol* 28, 1553–1565.

18 Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC and Lempicki RA (2003) DAVID: database for annotation, visualization, and integrated discovery. *Genome Biol* 4, P3.

19 Huang L, Wang T, Wang F, Hu X, Zhan G, Jin X, Zhang L and Li Y (2020) NUP37 silencing induces inhibition of cell proliferation, G1 phase cell cycle arrest and apoptosis in non-small cell lung cancer cells. *Pathol Res Pract* 216, 152836.

20 Wang L, Shen S, Xiao H, Ding F, Wang M, Li G and Hu F (2020) ARHGAP24 inhibits cell proliferation and cell cycle progression and induces apoptosis of lung cancer via a STAT6-WWP2-p27 axis. *Carcinogenesis* 41, 711–721.

21 Lu XX, Cao LY, Chen X, Xiao J, Zou Y and Chen Q (2016) PTEN inhibits cell proliferation, promotes cell apoptosis, and induces cell cycle arrest via downregulating the PI3K/AKT/hTERT pathway in lung adenocarcinoma A549 cells. *Biomed Res Int* 2016, 2476842.

22 Garcia D and Shaw RJ (2017) AMPK: mechanisms of cellular energy sensing and restoration of metabolic balance. *Mol Cell* 66, 789–800.

23 An HK, Kim KS, Lee JW, Park MH, Moon HI, Park SJ, Baik JS, Kim CH and Lee YC (2014) Mimulone-induced autophagy through p53-mediated AMPK/mTOR pathway increases caspase-mediated apoptotic cell death in A549 human lung cancer cells. *PLoS One* 9, e114607.

24 Jing K, Song KS, Shin S, Kim N, Jeong S, Oh HR, Park JH, Seo KS, Heo JY, Han J et al. (2011) Docosahexaenoic acid induces autophagy through p53/AMPK/mTOR signaling and promotes apoptosis in human cancer cells harboring wild-type p53. *Autophagy* 7, 1348–1358.

25 Li X, Tang X, Su J, Xu G, Zhao L and Qi Q (2019) Involvement of E-cadherin/AMPK/mTOR axis in LKB1-induced sensitivity of non-small cell lung cancer to gambogenic acid. *Biochem Pharmacol* 169, 113635.

26 Li Y, Liang R, Sun M, Li Z, Sheng H, Wang J, Xu P, Liu S, Yang W, Lu B et al. (2020) AMPK-dependent phosphorylation of HDAC8 triggers PGM1 expression to promote lung cancer cell survival under glucose starvation. *Cancer Lett* 478, 82–92.

27 Patra KC, Weerasekara VK and Bardeesy N (2019) AMPK-mediated lysosome biogenesis in lung cancer growth. *Cell Metab* 29, 238–240.

28 Eichner LJ, Brun SN, Herzig S, Young NP, Curtis SD, Shackelford DB, Shokhirev MN, Leblanc M, Vera LI, Hutchins A et al. (2019) Genetic analysis reveals AMPK is required to support tumor growth in murine kras-dependent lung cancer models. *Cell Metab* 29, e7.